Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7662365 | VALINOR | Polymer conjugates of opioid antagonists |
Oct, 2022
(1 year, 6 months ago) | |
US7786133 | VALINOR | Chemically modified small molecules |
Sep, 2028
(4 years from now) | |
US9012469 | VALINOR | Crystalline naloxol-peg conjugate |
Apr, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617530 | VALINOR | Polymer conjugates of opioid antagonists |
Oct, 2022
(1 year, 6 months ago) | |
US7056500 | VALINOR | Polymer conjugates of opioid antagonists |
Jun, 2024
(2 months from now) | |
US8067431 | VALINOR | Chemically modified small molecules |
Dec, 2024
(7 months from now) |
Movantik is owned by Valinor.
Movantik contains Naloxegol Oxalate.
Movantik has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Movantik are:
Movantik was authorised for market use on 16 September, 2014.
Movantik is available in tablet;oral dosage forms.
Movantik can be used as treatment of opioid-induced constipation.
Drug patent challenges can be filed against Movantik from 16 September, 2018.
The generics of Movantik are possible to be released after 02 April, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL